Global Epilepsy Drugs Market to grow with a CAGR of 3.09%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Epilepsy Drugs Market.
According
to TechSci Research report, “Global Epilepsy Drugs Market Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Epilepsy Drugs Market
has valued at USD 6.95 billion in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 3.09% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market. Emerging therapies are drivers for the global epilepsy drugs market.
These therapies represent new and innovative approaches to the treatment of
epilepsy, often with the goal of improving seizure control, reducing side
effects, and enhancing the quality of life for individuals living with the
condition. Pharmaceutical companies are continuously researching and developing
new epilepsy drugs with innovative mechanisms of action. These drugs aim to
provide better seizure control and improved tolerability compared to existing
options. Emerging therapies may be tailored to individual patients through
precision medicine approaches. Genetic testing and biomarker identification
help identify the most appropriate drugs and treatment plans for specific
epilepsy subtypes. Advances in biotechnology and understanding of epilepsy's
underlying mechanisms have led to the development of biological therapies, such
as gene therapies and monoclonal antibodies, which target specific molecular
pathways involved in epilepsy. Medical cannabis and cannabinoid-based
treatments have gained attention as potential options for epilepsy management,
particularly for individuals with drug-resistant epilepsy. Some cannabinoids,
like cannabidiol (CBD), have received regulatory approval for specific epilepsy
syndromes. Techniques like vagus nerve stimulation (VNS), responsive
neurostimulation (RNS), and transcranial magnetic stimulation (TMS) are
emerging as adjuvant therapies to help reduce seizures or improve seizure
control when medications alone are ineffective. Dietary therapies, including
the ketogenic diet, are considered emerging options for epilepsy management,
particularly in pediatric cases. These therapies may be used in conjunction
with or as alternatives to drug treatments.
Browse
over XX market data Figures and spread through XX
Pages and an in-depth TOC on " Global Epilepsy Drugs Market.”
Epilepsy is a persistent neurological
condition characterized by recurrent seizures resulting from abnormal
electrical brain activity. It is a chronic noncommunicable medical condition.
Seizures come in various forms, each involving involuntary movements that can
impact specific body regions or the entire body. Treatment choices encompass
medications, including first-generation, second-generation, and
third-generation drugs. In November
2020, UCB, a global pharmaceutical company, has received approval from the U.S.
Food and Drug Administration (FDA) for VIMPAT (lacosamide) CV to be used as an
adjunctive therapy for the treatment of primary generalized tonic-clonic
seizures (PGTCS) in patients aged four and older. This approval also includes
VIMPAT injection for intravenous use in children aged four and older. PGTCS is
a specific type of seizure that impacts the entire brain, involving both brain
hemispheres from the outset and leading to muscle stiffness and convulsions
lasting for a few minutes. Epilepsy is a common symptom associated with various
chronic brain disorders. It stands as the fourth most prevalent neurological
condition globally, affecting approximately 65 million individuals. Epilepsy
can affect people of all ages, ethnic backgrounds, and genders and is
characterized by one or more unprovoked epileptic seizures, which carry a risk
of further seizures.Stigma
and misinformation are significant challenges in the global epilepsy drugs
market and in the broader context of epilepsy management. These challenges can
have various negative impacts on individuals with epilepsy and the overall
healthcare landscape. Stigma and misconceptions about epilepsy can lead to
delayed diagnosis and treatment. People may be hesitant to seek medical help
due to fear of social stigma, discrimination, or a lack of understanding about
the condition. Delayed treatment can result in uncontrolled seizures and more
severe health consequences. Individuals with epilepsy often face social
isolation, bullying, and discrimination. Stigmatization can lead to emotional
distress, anxiety, depression, and low self-esteem. These psychosocial effects
can impact a patient's overall well-being and may affect their adherence to
medication and treatment plans. Stigma can limit the opportunities and quality
of life for people with epilepsy. Discrimination in education, employment, and
social interactions may lead to social exclusion and economic hardships. Stigma
and misinformation can contribute to medication non-adherence. Some individuals
may stop taking their epilepsy drugs due to perceived social stigma or
misinformation about the safety and effectiveness of treatment. Healthcare
providers may face challenges in educating and supporting patients with
epilepsy due to prevailing misinformation and societal biases. Addressing
stigma and providing accurate information is essential for effective patient
care.
Global Epilepsy Drugs Market is segmented based on Drugs,
Distribution Channel, and by region. Based
on the Drugs, Global Epilepsy Drugs Market is segmented into First Generation Anti-epileptics, Second
Generation Anti-epileptics, Third Generation Anti-epileptics. First-generation
anti-epileptic drugs (AEDs), also known as traditional or older AEDs, are a
group of medications that were among the first to be developed and approved for
the treatment of epilepsy. These drugs have been in use for several decades and
were initially introduced in the mid-20th century. While they remain important
in epilepsy management, newer, second-generation AEDs have been developed with
improved safety and efficacy profiles. First-generation AEDs act on various
mechanisms within the brain to prevent or reduce epileptic seizures.
First-generation AEDs are known for their side effects, which can vary among
different drugs but may include drowsiness, dizziness, memory problems, mood
changes, and reduced cognitive function. Long-term use of some of these drugs
may lead to more severe side effects, such as liver toxicity, bone health
issues, or skin reactions. Many first-generation AEDs can interact with other
medications, potentially affecting their efficacy or leading to adverse effects.
Drug interactions are an important consideration for patients and healthcare
providers. Based on Region, North
America held the largest share in the Global
Epilepsy Drugs Market. North America has well-established epilepsy
advocacy organizations and awareness campaigns that help reduce the stigma
associated with epilepsy and educate the public and healthcare professionals.
Increased awareness often leads to more people seeking diagnosis and treatment.
The highly competitive pharmaceutical market in North America can lead to
aggressive marketing and promotion of epilepsy drugs, resulting in increased
sales and market dominance. Regulatory agencies such as the U.S. Food and Drug
Administration (FDA) play a crucial role in the approval and oversight of
epilepsy drugs. The efficient and transparent regulatory processes in North
America contribute to the availability of a wide range of epilepsy medications.
North America has a large pool of neurologists and healthcare professionals
with expertise in epilepsy diagnosis and treatment. This expertise ensures that
patients receive the most appropriate and up-to-date care.
Some of the major companies
operating in the Global Epilepsy Drugs
Market include:
- Novartis
AG
- GlaxoSmithKline
plc
- Sanofi
S.Aa
- UCB
S.A.
- Abbott
Laboratories
- Bausch
Health Companies, Inc
- Viatris
Inc.
- Johnson
& Johnson
- Sumitomo
Pharma Co., Ltd
- H.
Lundbeck A/S
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Epilepsy Drugs. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Epilepsy
Drugs Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
Epilepsy
Drugs Market by Drugs (First Generation Anti-epileptics, Second
Generation Anti-epileptics, Third Generation Anti-epileptics), By Distribution
Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Region, By Competition
Forecast & Opportunities, 2018-2028F has evaluated the future growth
potential of Global Epilepsy Drugs Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide innovative market intelligence and help decision makers take
sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global Epilepsy Drugs Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com